Literature DB >> 21029110

Monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures.

G Walther-Wenke1, C H Wirsing von König, W Däubener, M Heiden, J Hoch, B Hornei, P Volkers.   

Abstract

BACKGROUND AND OBJECTIVES: National guidelines for monitoring bacterial contamination of blood components were introduced in Germany in 1997. Between 1998 and 2002, numerous measures were implemented to prevent bacterial contamination. This study investigates their impact on contamination rates.
MATERIALS AND METHODS: Culture-based testing for bacterial detection on a random sample of blood components is part of routine quality control in German blood establishments. Using standardized questionnaires, data from the production periods 1998, 2001 and 2005/2006 were collected and analysed.
RESULTS: The bacterial contamination rate of RBCs was reduced from 0·157% in 1998 to 0·029% in 2005/2006 (P<0·001). While the contamination rate of apheresis PCs remained nearly unchanged over the years, it dramatically decreased for pooled PCs by 70% to a contamination rate of 0·158% (P=0·001) within the last observation period, similar to that of apheresis PCs. The contamination rate of plasma decreased from 0·100% in 1998 to 0·019% in 2005/2006 (P=0·002).
CONCLUSIONS: Precautionary measures significantly reduced bacterial contamination rates of blood components. Long-term monitoring with standardized methods is appropriate to evaluate the cumulative effect of contamination-preventing measures.
© 2010 The Author(s). Vox Sanguinis © 2010 International Society of Blood Transfusion.

Mesh:

Year:  2010        PMID: 21029110     DOI: 10.1111/j.1423-0410.2010.01432.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  10 in total

1.  Effect of Safety Measures on Bacterial Contamination Rates of Blood Components in Germany.

Authors:  Gabriele Walther-Wenke; Walter Däubener; Margarethe Heiden; Jochen Hoch; Britt Hornei; Peter Volkers; Carl Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2011-07-11       Impact factor: 3.747

2.  Implementation of Bacterial Detection Methods into Blood Donor Screening - Overview of Different Technologies.

Authors:  Michael Schmidt; Walid Sireis; Erhard Seifried
Journal:  Transfus Med Hemother       Date:  2011-07-07       Impact factor: 3.747

3.  Pathogenicity of Bacteria Contaminating Blood Products.

Authors:  Sören G Gatermann
Journal:  Transfus Med Hemother       Date:  2011-07-12       Impact factor: 3.747

4.  Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis.

Authors:  Maria Agapova; Elzbieta Lachert; Ewa Brojer; Magdalena Letowska; Piotr Grabarczyk; Brian Custer
Journal:  Transfus Med Hemother       Date:  2015-04-16       Impact factor: 3.747

Review 5.  One size will never fit all: the future of research in pediatric transfusion medicine.

Authors:  Cassandra D Josephson; Traci Heath Mondoro; Daniel R Ambruso; Rosa Sanchez; Steven R Sloan; Naomi L C Luban; John A Widness
Journal:  Pediatr Res       Date:  2014-08-13       Impact factor: 3.756

Review 6.  Diagnostic methods for platelet bacteria screening: current status and developments.

Authors:  Melanie Störmer; Tanja Vollmer
Journal:  Transfus Med Hemother       Date:  2013-12-30       Impact factor: 3.747

7.  Evaluation of Risk Minimisation Measures for Blood Components - Based on Reporting Rates of Transfusion-Transmitted Reactions (1997-2013).

Authors:  Markus B Funk; Margarethe Heiden; Peter Volkers; Annette Lohmann; Brigitte Keller-Stanislawski
Journal:  Transfus Med Hemother       Date:  2015-05-05       Impact factor: 3.747

8.  Evaluation of Mirasol pathogen reduction system by artificially contaminating platelet concentrates with Staphylococcus epidermidis: A pilot study from India.

Authors:  Kabita Chatterjee; Shamsuz Zaman; Rahul Chaurasia; Surinder Singh; Shawn D Keil; Shalini Tewari; Akanksha Bisht; Nitin Agarwal; Diptiranjan Rout; Subhash Chand; Kallol Saha
Journal:  Asian J Transfus Sci       Date:  2016 Jul-Dec

9.  Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model.

Authors:  Katherine M Prioli; Julie Katz Karp; Nina M Lyons; Vera Chrebtow; Jay H Herman; Laura T Pizzi
Journal:  Appl Health Econ Health Policy       Date:  2018-12       Impact factor: 2.561

10.  Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination.

Authors:  Shawn D Keil; Nick Hovenga; Denise Gilmour; Susanne Marschner; Raymond Goodrich
Journal:  J Vis Exp       Date:  2015-08-24       Impact factor: 1.355

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.